AC Immune was named by FierceBiotech today as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection.
According to FierceBiotech AC Immune is one of the most promising private biotechnology companies. “AC Immune has tackled Alzheimer’s, one of the toughest disease targets in biotech,” says FierceBiotech Editor John Carroll. “But its carefully crafted antibodies have attracted the attention of Genentech, a Roche subsidiary with a world-class reputation in R&D which has partnered on two of its programs. And now investigators are setting the stage for a pioneering study that will test AC Immune’s crenezumab in a unique at-risk population. Groundbreaking science makes AC Immune one of the world’s top biotech companies. We’ll be following its progress closely.”
Andrea Pfeifer, CEO of AC Immune commented: “We are extremely pleased and honored to be among this year’s Fierce 15. This recognition is shared by all those who have worked with such skill and dedication over the past nine years: our employees, our investors, our partners and the broad Alzheimer’s disease community. We are proud to have built one of the broadest and most advanced Alzheimer’s pipelines in the industry, and we will continue our passionate search for effective therapies and diagnostics for this devastating neurodegenerative disease, one of the biggest healthcare problems of this century.”
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition.
An internationally recognized daily newsletter reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick, authoritative briefing on the day's top stories. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
The 2012 Fierce 15 companies were recognized yesterday at the BioPharm America conference in Boston. A complete list of "Fierce 15" companies is available online at www.fiercebiotech.com.
AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s disease drug development. Since its foundation in 2003, AC Immune has raised CHF 64 million from private investors.
Please login or sign up to comment.
Commenting guidelines